(NYSE: SER) Takes Over Today's Top Watchlist Spot Behind 5 Potential Catalysts (Low Float)

Pursuing cutting-edge therapies for tough neurological diseases

*Sponsored (NYSE: SER) Takes Over Today's Top Watchlist Spot Behind 5 Potential Catalysts (Low Float) August 27th Greetings, Friend! Pursuing cutting-edge therapies for tough neurological diseases, this NYSE American profile remains largely overlooked. How much longer? That’s a great question. With next-gen molecules, their pipeline spans a range of central nervous system disorders and more. Partnerships back research into RNA medicines tied to cancer immunotherapy and gene therapy. This forward-leaning drug development strategy shows a clear push to open new medical possibilities—making the company worth watching for those tracking emerging treatments. Add in a float just above 3Mn shares (meaning volatility potential), strong analyst targets, bullish technicals, and recent corporate actions pointing to transformative progress, and it’s easy to see why this biopharma is on my radar. Take a look at this NYSE American idea: Serina Therapeutics, Inc. (NYSE: SER) Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). A Next-Gen Polymer Therapeutic Serina Therapeutics' proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline). During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.” This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates. As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations. While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules. POZ Delivers Key Advantages POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself. Enabling Continuous Drug Delivery And Why It Matters Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. They have to be monitored and dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients. Administered Subcutaneously, POZ Provides Extended Delivery Enabled by POZ Serina Therapeutics is developing proprietary drugs to treat neurological diseases. Its lead product candidate, SER-252 for advanced Parkinson’s disease, is expected to enter clinical trials in 2025. Current discovery and development efforts include a focus on unlocking the potential of molecules across a range of CNS indications and beyond. The company’s POZ platform partners are at the forefront of advancing novel RNA medicines in vaccine immunology, cancer immunotherapy, and gene therapy. Find Sources And More Here: SER Website. SER Presentation. ----- 5 Potential Catalysts Put (NYSE: SER) On Radar Notice!  No. 1: This NYSE American Profile Has A Low Float. With roughly 3.08Mn shares in its float, volatility potential could be significantly heightened on a daily basis for SER. No. 2: Several Bullish Technical Indicators May Suggest A Developing Trend Worth Watching Closely. When the closing bell rang on Tuesday, Barchart was reporting SER to have several technicals to be triggered across the short, medium, and long term. In fact, the website shares that a total of 6 technical indicators are currently triggered. No. 3: FDA Feedback Strengthens Serina Therapeutics Pathway With SER-252 Advancement. Serina Therapeutics achieved a key milestone with FDA backing to advance its lead Parkinson’s candidate, SER-252, into a registrational program under the efficient 505(b)(2) NDA pathway. The agency’s supportive feedback validates Serina’s POZ technology platform and streamlines potential approval while maintaining rigorous clinical standards. IND filing is targeted for Q4 2025, with U.S. patient enrollment anticipated in Q1 2026 and Australian dosing scheduled to begin this year. Serina’s plan highlights strong regulatory alignment, capital efficiency, and commitment to delivering transformative treatment for people living with advanced Parkinson’s disease. No. 4: Serina Therapeutics Advances Innovative POZ-VMAT2i For Tardive Dyskinesia Treatment. Serina Therapeutics is advancing SER-270 (POZ-VMAT2i), a novel once-weekly injectable VMAT2 inhibitor, designed to transform treatment for underserved tardive dyskinesia (TD) patients. Unlike oral therapies, POZ-VMAT2i leverages Serina’s proprietary POZ platform to overcome adherence, access, and administration challenges faced by patients with psychiatric conditions, dysphagia, or those managed with long-acting injectables. By addressing real-world barriers, Serina positions POZ-VMAT2i as a first-of-its-kind solution in a $3.7Bn and growing market. The company also plans expansion into Huntington’s chorea, highlighting Serina’s commitment to delivering truly patient-centered therapeutic innovation. No. 5: Two Analyst Targets Point To Strong Upside Potential For SER. Not just one, but two different analysts are suggesting SER to be undervalued from current chart levels. Shared over at TipRanks, an H.C. Wainwright analyst has tagged SER with a $15 target. From its close on Tuesday, that target provides SER with a potential upside of over 175%! Additionally, a JonesTrading analyst has given SER an $11.00 target. That target gives SER a potential upside of 100+% from its closing valuation Tuesday. ----- That's it! We're officially kicking off coverage on Serina Therapeutics, Inc. (NYSE: SER). Be on the lookout for updates coming soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 08/26/2025 and ending on 08/27/2025 to publicly disseminate information about (SER:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (SER:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ser-xcp7b/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice